Phase 1 study of REGN1400 (anti-ErbB3) combined with erlotinib or cetuximab in patients (pts) with advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck cancer (SCCHN).

Abstract

2516 Background: REGN1400 (R) is a fully human mAb targeting ErbB3. Preclinically, dual inhibition of ErbB3 and EGFR confers augmented antitumor potency. This first-in-human dose escalation trial e...